|
|
Adjumer™ |
|
Vaxjo ID |
39 |
|
Vaccine Adjuvant Name |
Adjumer™ |
|
Alternative Names |
PCPP salt; polyphosphazene; polyidi (carboxylatophenoxy) lphosphazene |
|
Adjuvant VO ID |
VO_0000351
|
|
Description |
In soluble form, Adjumer serves as an adjuvant for parenteral administration but can be cross - linked to form microsphere hydrogel for mucosal vaccination (Jorgensen et al., 2009). |
|
Stage of Development |
Clinical Trial |
|
Components |
PCPP salt; polyphosphazene; polyidi(carboxylatophenoxy)lphosphazene (Vogel and Powell, 1995). |
|
Molecular Weight |
>700,000 daltons |
|
Appearance |
Solid: beige to off white powder. Aqueous solution: clear, colorless liquid |
|
Storage |
Powder is stable at -20° C. Solution is stable at 4° C. |
|
Function |
Induces a sustained antibody response in mice after a single parenteral immunization. Antibody responses include antigen specific IgG1 and IgG2a. Sustained IgG and IgA responses are also induced in mice after mucosal immunization (Vogel and Powell, 1995). |
|
Safety |
Has been evaluated in human phase I and II clinical trials. Adjumer™ has been well tolerated with no adverse reactions reported (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Jorgensen et al., 2009: Lene Jorgensen, Hanne Mørck Nielsen, S. Moein Moghimi. Chapter 6. The Innate Immune Responses Adjuvants and Delivery Systems. .. Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines. 2009. John Wiley & Sons, Ltd, Chichester, UK.
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
